GSK Looks To Expand OTC Reach With CNS Brands
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will pay nearly five times CNS's 12-month sales total to widen its consumer reach with the acquisition of CNS, the Minneapolis-based maker of Breathe Right and FiberChoice products
You may also be interested in...
GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty
GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says
GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty
GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says
GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty
GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says